Amta

Amta Biopharma is a clinical-stage biotechnology company focused on the development of innovative therapies for autoimmune and inflammatory diseases. The company specializes in targeting the IL-17 and IL-23 pathways, which are critical drivers of various chronic inflammatory conditions. Amta's lead programs include small molecule inhibitors and monoclonal antibodies designed to provide more effective and convenient treatment options for patients with psoriasis and related disorders. By leveraging its expertise in immunology and drug discovery, Amta aims to address significant unmet medical needs in the global healthcare market. The company is actively advancing its pipeline through clinical trials to demonstrate the safety and efficacy of its novel therapeutic candidates.